topotecan has been researched along with etoposide in 208 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 22 (10.58) | 18.2507 |
| 2000's | 111 (53.37) | 29.6817 |
| 2010's | 60 (28.85) | 24.3611 |
| 2020's | 15 (7.21) | 2.80 |
| Authors | Studies |
|---|---|
| Bigg, DC; Camara, J; Demarquay, D; Harnett, J; Kasprzyk, PG; Lavergne, O; Lesueur-Ginot, L; Pla Rodas, F; Pommier, J; Pons, D; Prévost, G; Rolland, A; Schiano-Liberatore, AM; Ulibarri, G | 1 |
| Allen, JD; Buitelaar, M; Schinkel, AH; Van Dort, SC; van Tellingen, O | 1 |
| Gibbons, S; Kaatz, GW; Zloh, M | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Ghosh, I; Manoharlal, R; Prakash, O; Prasad, R; Puri, N; Sharma, M | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Dong, G; Guo, Z; Miao, Z; Sheng, C; Wang, S; Yao, J; Zhang, W; Zhang, Y | 1 |
| Cho, H; Elkamhawy, A; Heo, JC; Kim, HY; Kim, KH; Lee, CO; Nam, DH; Pae, AN; Park, WK; Roh, EJ; Seol, HJ; Viswanath, AN; Yang, H | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bhattacharya, D; Das, BB; Das, SK; Ghosh, A; Kundu, B; Mukherjee, A; Pal, S; Paul Chowdhuri, S; Sarkar, D; Talukdar, A | 1 |
| Chen, S; Dong, G; Li, X; Liu, D; Ma, Z; Sheng, C; Wu, S | 1 |
| Dai, X; Jiang, T; Li, J; Qi, X; Wu, G; Yin, R; Yu, R; Zhang, G | 1 |
| Kaufmann, SH | 1 |
| Capranico, G; D'Incalci, M; Garattini, S; Giaccone, G; Zunino, F | 1 |
| Kim, K | 1 |
| Berger, NA; Chatterjee, S; Cheng, MF | 1 |
| Bosl, GJ; Chou, TC; Motzer, RJ; Tong, Y | 1 |
| Ellis, AL; Nowak, B; Plunkett, W; Zwelling, LA | 1 |
| DeVore, R; Glick, J; Hutson, P; Johnson, D; Kim, K; Schiller, JH; Stewart, J | 1 |
| Fossella, FV; Glisson, BS; Hong, WK; Lee, JS; Murphy, WK; Perez-Soler, R; Shin, DM | 1 |
| Ganapathi, R; Grabowski, D | 1 |
| Bonner, JA; Kozelsky, TF | 1 |
| Berger, NA; Gordon, NH; Mackay, W; Whitacre, CM; Zborowska, E | 1 |
| Basi, GS; Earnshaw, WC; Eischen, CM; Kaufmann, SH; Kottke, TJ; Leibson, PJ; Martins, LM; Tung, JS | 1 |
| Ozols, RF | 1 |
| Negoro, S | 1 |
| Beijnen, JH; Dubbelman, AC; Groot, Y; Herben, VM; Mandjes, IA; ten Bokkel Huinink, WW; van Gortel-van Zomeren, DM | 1 |
| Kaufmann, SH; Rowinsky, EK | 1 |
| Burris, HA; Eckardt, JR; Eckhardt, SG; Ganapathi, R; Hammond, LA; Hodges, S; Kuhn, JG; Rodriguez, GA; Rothenberg, ML; Rowinsky, EK; Von Hoff, DD; Weiss, GR | 1 |
| Cnaan, A; Janss, AJ; Levow, C; Phillips, PC; Shpilsky, A; Sutton, L; Zhao, H | 1 |
| Beare, S; Crump, M; Eisenhauer, E; Hedley, D; Lipton, J; Minden, M; Shepherd, F; Stewart, K; Sutton, D | 1 |
| Beran, M; Cortes, J; Estey, E; Kantarjian, H; Koller, C; O'Brien, S; Vey, N | 1 |
| Groshen, S; Keshelava, N; Reynolds, CP | 1 |
| Atassi, G; Guilbaud, N; Jan, M; Kraus-Berthier, L; Naze, M; Pierré, A | 1 |
| Boisdron-Celle, M; Boulanger, N; Gamelin, E | 1 |
| Bianco, AR; Caputo, R; Ciardiello, F; De Laurentiis, M; De Placido, S; Pomatico, G; Tortora, G | 1 |
| Bigg, DC; Bronckart, Y; Chaboteaux, C; da Costa, PM; Decaestecker, C; Gordover, L; Harper, L; Kiss, R; Lavergne, O; Lesueur-Ginot, L; Malonne, H; Philippart, P | 1 |
| Beijnen, JH; Mathôt, RA; Schellens, JH; van den Bongard, HJ | 1 |
| Lambrou, N; Trimble, EL | 1 |
| Amo-Takyi, BK; Boabang, P; Kohlhagen, H; Kurbacher, CM; Waida, A | 1 |
| Ahmed, T; Durrani, H; Kancherla, RR; Mannancheril, A; Nair, JS; Seiter, K; Tse-Dinh, YC | 1 |
| Kancherla, R; Nair, JS; Seiter, K; Traganos, F; Tse-Dinh, YC | 1 |
| Fanucchi, MP; Giblin, J; McGuire, WP | 1 |
| Berger, NA; Berger, SJ; Dowlati, A; Gordon, NH; Gosky, DM; Hoppel, CL; Ingalls, ST; Levitan, N; Remick, SC | 1 |
| Malik, IA | 1 |
| Adak, S; Cella, D; DeVore, RF; Johnson, DH; Schiller, JH | 1 |
| Dingemans, AC; Giaccone, G; Postmus, PE; Scagliotti, GV; Span, S; van Ark-Otte, J; van der Valk, P | 1 |
| Baguley, BC; Baker, M; Bootle, D; Charlton, PA; Dangerfield, W; Denny, WA; Kofler, B; Mistry, P; Okiji, S; Stewart, AJ | 1 |
| Burris, HA; Greco, FA; Hainsworth, JD | 1 |
| Clark, PI; Hannigan, K; Marshall, E; O'Neill, P; Ross, G; Smith, D | 1 |
| Cliby, WA; Kaufmann, SH; Lewis, KA; Lilly, KK | 1 |
| Hassan, SB; Jonsson, E; Karlsson, MO; Larsson, R | 1 |
| du Bois, A | 1 |
| Boccieri, MG; Bruschi, G; Lo Re, G; Saracchini, S; Toffoli, G; Tumolo, S | 1 |
| Cronk, M; Dunstan, HM; Evans, DR; Goehle, S; Lamb, JR; Ludlow, C; Simon, JA; Szankasi, P | 1 |
| Cheng, YC; Lam, W; Park, SY | 1 |
| Giaccone, G; Huisman, C; Postmus, PE; Smit, EF | 1 |
| Thigpen, T | 1 |
| Bookman, MA | 2 |
| Anderson, JR; Barr, FG; Crist, WM; Donaldson, SS; Maurer, HM; Pappo, AS; Qualman, SJ; Raney, RB; Wiener, ES | 1 |
| Leslie, KK | 1 |
| Lichtman, SM; Skirvin, JA | 1 |
| Chen, S; Gomez, SP; Mainwaring, MG; McCarley, D | 1 |
| Hensley, ML | 1 |
| Braylan, R; Chen, SF; Fieniewicz, KJ; Gomez, SP; Kahn, S; Leather, H; Lynch, J; Mainwaring, MG; May, WS; Moreb, J; Reddy, V; Rimsza, LM; Rowe, TC; Weeks, FW; Wingard, JR | 1 |
| Kim, R; Kocarek, TA; Lan, L; Schuetz, E; Schuetz, J; Strom, S; Yasuda, K | 1 |
| Chak, K; Chan, AT; Johnson, P; Lee, TW; Leung, TW; Mok, TS; Wong, H; Yeo, W; Yim, A; Yu, KH; Zee, B | 1 |
| Deslandes, E; Gauduchon, P; Godard, T; Poul, JM; Sichel, F | 1 |
| Agelidou, M; Ferdoutsis, E; Georgoulias, V; Kalbakis, K; Kouroussis, Ch; Magkanas, E; Mavroudis, D; Samonis, G; Souglakos, J; Toumbis, M; Tselepatiotis, E; Tzanakis, N; Veslemes, M; Ziotopoulos, P | 1 |
| Couban, S; Crump, M; Eisenhauer, E; Gluck, S; Hoskins, P; Maksymiuk, A; Matthews, S; Meyer, R; Rudinskas, L; Zanke, B | 1 |
| D'Orazio, A; Gibson, AD | 1 |
| Adams, R; Albritton, K; Coffin, C; Goldsby, R; Pulsipher, M; Wagner, L | 1 |
| Gore, SD; Malek, SN | 1 |
| Berger, SJ; Cooper, BW; Donaher, E; Gerson, SL; Gosky, DM; Green, SB; Hoppel, CL; Ingalls, ST; Lazarus, HM; Li, X; Rosenthal, NS | 1 |
| Agelaki, S; Androulakis, N; Apostolopoulou, F; Blazoyiannakis, G; Georgoulias, V; Kakolyris, S; Kouroussis, Ch; Magkanas, E; Mavroudis, D; Pavlakou, G; Samonis, G; Vardakis, N; Veslemes, M | 1 |
| Corbacioglu, S; Eber, S; Gungor, T; Hummerjohann, J; Niggli, F | 1 |
| Fedier, A; Fink, D; Haller, U; Lenherr, L; Schwarz, VA; Steiner, RA | 1 |
| Bauman, MD; Hatfield, AK; Hillman, S; Jett, JR; Kugler, JW; Levitt, R; Mailliard, JA; Marks, RS; Morton, RF | 1 |
| Coldman, BJ; Fossella, FV; Glisson, BS; Komaki, R; Kurie, JM; Lee, JS; Lu, C; Palmer, JL; Pisters, KM; Shin, DM | 1 |
| Bauman, MD; Ebbert, LP; Kugler, JW; Mahoney, MR; Mailliard, JA; Marks, RS; Schaefer, PL; Sloan, JA; Tazelaar, HD; Wiesenfeld, M | 1 |
| Aisner, J; Beers, S; Locsin, S; Musanti, R; Rubin, EH; Smith, S | 1 |
| Fiorica, JV | 1 |
| Greco, FA | 1 |
| Bally, M; Hu, Y; Krishan, A; Mayer, LD; Nie, W; Sridhar, KS | 1 |
| Ali, K; Fung, MF; Hopkins, L; Le, T; Leis, A; Pahwa, P; Reeder, B; Wright, K | 1 |
| Castellano, A; Cozza, R; De Laurentis, C; De Sio, L; Deb, G; Dominici, C; Donfrancesco, A; Fidani, P; Ilari, I; Inserra, A; Jenkner, A; Milano, GM | 1 |
| Catapano, CV; Freeman, KD; Green, MR; Mushtaq, C; Oakhill, G; Pacheco, D; Rocha Lima, CM; Sherman, CA | 1 |
| Buller, RE; Geisler, JP; Lush, R; Sanders, L; Shahin, MS; Sood, AK; Sorosky, JI; Sullivan, D | 1 |
| de Cremoux, P; Decaudin, D; Fréneaux, P; Judde, JG; Livartowski, A; Nemati, F; Pouillart, P; Poupon, MF; Sastre, X; Tran-Perennou, C | 1 |
| Herzog, TJ | 1 |
| Engelholm, SA; Gronlund, B; Horvath, G; Mäenpää, J; Ridderheim, M | 1 |
| Buchholz, E; Gatzemeier, U; Goetz, E; Groth, G; Manegold, C; Reck, M | 1 |
| Braybrooke, JP; Davies, SL; Echeta, C; Flanagan, E; Ganesan, TS; Hickson, ID; Joel, S; Levitt, NC; Madhusudan, S; Propper, DJ; Te Poele, R | 1 |
| Appleman, LJ; Campos, SM; Clark, JW; Eder, JP; Fuller, AF; Goodman, A; Matulonis, UA; Penson, RT; Roche, M; Seiden, MV | 1 |
| Breton, JL; Cardenal, F; Gervais, R; Lymboura, M; Mattson, K; Preston, A; Quoix, E; Ross, G; Schramel, F; Wilson, J | 1 |
| Cheng, AL; Chu, YC; Huang, CJ; Whang-Peng, J; Yang, CH; Yang, CS; Yang, PC | 1 |
| Donahue, A; Faucette, S; Gillenwater, HH; Kirstein, MN; Lindley, C; McCune, JS; Moore, D; Shord, S; Socinski, MA; Stewart, CF; Zamboni, WC | 1 |
| Dyer, MA; Egorin, M; Gray, JK; Laurie, NA; Leggas, M; Relling, M; Stewart, C; Zhang, J | 1 |
| Burris, HA; Corso, SW; Erland, JB; Greco, FA; Hainsworth, JD; Joseph, G; Morrissey, LH; Spigel, DR; Spremulli, E; Thompson, DS | 1 |
| Brown, LM; Cowen, RL; Debray, C; Erler, JT; Eustace, A; Parker, CA; Sheppard, FC; Stratford, IJ; Williams, KJ | 1 |
| Escherich, G; Hassenpflug, WA; Horstmann, MA; Janka, G; Kabisch, H; zur Stadt, U | 1 |
| Agelidou, A; Agelidou, M; Boukovinas, J; Georgoulias, V; Gerogianni, A; Ignatiadis, M; Mavroudis, D; Nikolakopoulos, J; Pavlakou, G; Syrigos, K; Tselepatiotis, E; Veslemes, M | 1 |
| Bell, JG; Fusco, NL; Markman, M; Rose, PG | 1 |
| Cheung, IY; Cheung, NK; Kramer, K; Kushner, BH; Modak, S | 1 |
| Argentieri, D; Falotico, R; Parry, TJ; Siekierka, J; Tallarida, RJ; Thyagarajan, R | 1 |
| Perry, MC | 1 |
| Brannon, S; Crofts, TE; Eckardt, JR; Papai, Z; Ross, G; Tomova, A; Tzekova, V; von Pawel, J; Wissel, P | 1 |
| Fournel, P | 1 |
| Anderson, JR; Breitfeld, PP; Lager, JJ; Lyden, ER; Meyer, WH; Pappo, AS | 1 |
| Fangusaro, J; Finlay, J; Rook, J; Rosser, T | 1 |
| Chatelut, E; Henningsson, A; Karlsson, MO; Kloft, C; Wallin, J | 1 |
| Al Omari, A; Case, D; Miller, AA; Murry, DJ | 1 |
| Anderson, E; Andrews, C; Bjurstrom, T; Blackwell, S; Campagna, L; Crawford, J; Garst, J; Herndon, JE; Maravich-May, D; Padilla, K; Shafman, T | 1 |
| Al Harbi, T; Al-Faris, N; Doyle, J; Gassas, A; Goia, C; Pappo, A | 1 |
| Berthold, F; Hero, B; Klingebiel, T; Längler, A; Simon, T | 1 |
| Bot, BM; Garces, YI; Jett, JR; Kozelsky, TF; Mandrekar, SJ; Martens, JM; Moore, DF; Okuno, SH; Schild, SE; Soori, GS; Wender, DB | 1 |
| Aydiner, A; Camlica, H; Derin, D; Guney, N; Tas, F; Topuz, E | 1 |
| Cheng, S; Evans, WK; Shepherd, FA; Stys-Norman, D | 1 |
| Berthold, F; Claviez, A; Frühwald, MC; Harnischmacher, U; Hero, B; Jorch, N; Längler, A; Simon, T | 1 |
| Chang, J; Cheon, SH; Cho, BC; Choi, HJ; Jung, JY; Kim, JH; Kim, SK; Shin, SJ; Sohn, JH | 1 |
| Bogart, JA; Green, MR; Hodgson, LD; Miller, AA; Radford, JE; Rocha Lima, CM; Vokes, EE; Wang, XF | 1 |
| Chen, G; Guo, Y; Ma, D; Tian, X; Weng, D; Xing, H | 1 |
| Arimura, K; Armstrong, DL; Bhattacharjee, MB; Boerkoel, CF; Champoux, JJ; Choi, K; Deguchi, K; Hirano, R; Huang, C; Inoue, K; Interthal, H; Izumo, S; Nakamura, T; Northrop, JL; Salih, MA; Takashima, H; Umehara, F | 1 |
| Lehoczky, O; Pulay, T | 1 |
| Duh, MS; Lefebvre, P; Neary, M; Reynolds Weiner, J; Skarin, AT | 1 |
| Aisner, J; Collazo, C; Dutta, J; Gharibo, M; Gounder, M; Lin, Y; Nazar, A; Rubin, EH; Saleem, A; Saraiya, B; Schaar, D; Shih, W; Strair, RK; Zimmerman, L | 1 |
| Camara, O; Keil, E; Klare, P; Lichtenegger, W; Oskay-Oezcelik, G; Paulenz, A; Sehouli, J; Sommer, H; Stauch, M; Stengel, D; Zeimet, AG | 1 |
| Castleberry, R; Kletzel, M; Kretschmar, C; London, WB; Marcus, R; Murray, K; Zage, PE; Zhang, Y | 1 |
| Ross, HJ; Seung, SK | 1 |
| Budning, A; Chan, HS; Dai, S; Dimaras, H; Doyle, J; Drake, J; Gallie, BL; Halliday, W; Héon, E | 1 |
| Friedrichs, N; Gorschlüter, M; Gressner, O; Mey, U; Popp, H; Sauerbruch, T; Schmidt-Wolf, IG; Strehl, J | 1 |
| Bohr, VA; Christmann, M; Gestrich, C; Kaina, B; Roos, WP; Tomicic, MT | 1 |
| Hann, CL; Rudin, CM | 1 |
| Choi, YJ; Jang, WS; Kim, CH; Lee, JC; Lee, SJ; Lee, SS; Rho, JK | 1 |
| Karp, J | 1 |
| Kakavelas, P; Kontakiotis, T; Lithoxopoulou, H; Mylonaki, E; Rapti, E; Tsiouda, T; Zarogoulidis, K; Zarogoulidis, P; Zarogoulidou, V | 1 |
| Chekerov, R; Fotopoulou, C; Karavas, A; Lichtenegger, W; Sehouli, J; Trappe, R | 1 |
| Ji, W; Lü, JM; Ou, GF; Ren, H; Wang, LH; Wang, XZ; Yin, WB; Zhou, ZM | 1 |
| Friberg, LE; Hansson, EK; Karlsson, MO; Lindman, H; Sandström, M; Wallin, JE | 1 |
| Arvelo, F; Assayag, F; Bourgeois, Y; Daniel, C; Decaudin, D; Froget, B; Legrier, ME; Livartowski, A; Némati, F; Poupon, MF | 1 |
| García-Sanz, R; González-López, TJ; Graciani, IF; Hermida, G; San Miguel, JF; Vázquez, L | 1 |
| Tonini, GP | 1 |
| Bodiagin, DA; Pokrovskiĭ, VS; Treshchalin, MI; Treshchalina, EM | 1 |
| Agelaki, S; Agelidou, A; Agelidou, M; Androulakis, N; Baka, S; Georgoulias, V; Gerogianni, A; Kalbakis, K; Kotsakis, A; Mavroudis, D; Papakotoulas, P; Pavlakou, G; Tsaroucha, E; Vamvakas, L; Veslemes, M | 1 |
| Kivivuori, SM; Lönnqvist, T; Riikonen, P; Saarinen-Pihkala, UM; Valanne, L | 1 |
| Brigulová, K; Cervinka, M; Sedláková, I; Tošner, J | 1 |
| Athanasopoulos, A; Daladimos, T; Karabelis, A; Kosmas, C; Mylonakis, N; Theotikos, E; Tsakonas, G | 2 |
| Aglione, S; Bareggi, C; Blackhall, F; Califano, R; Collovà, E; Farina, G; Fatigoni, S; Galetta, D; Gallerani, E; Garassino, MC; Ghidini, A; La Verde, N; Lo Dico, M; Lorigan, P; Mancuso, A; Martelli, O; Michetti, G; Rossi, A; Saggia, C; Thatcher, N; Torri, V | 1 |
| Castellano, A; De Ioris, MA; De Pasquale, MD; De Vito, R; Donfrancesco, A; Garganese, MC; Ilari, I; Inserra, A; Jenkner, A; Locatelli, F; Natali, G; Ravà, L | 1 |
| Kumabe, T; Niizuma, H; Osawa, S; Saito, R; Sonoda, Y; Tominaga, T; Watanabe, M | 1 |
| Chang, QY; Li, M; Li, XG; Li, YF; Liu, J; Song, PP; Tian, HM; Wang, XB; Wu, LY; Zhang, W; Zhao, D | 1 |
| Glimelius, B; Lahn, M | 1 |
| Babyn, P; Chan, HS; Dimaras, H; Doyle, J; Gallie, BL; Halliday, W; Héon, E; Paton, KE; Strahlendorf, C | 1 |
| Cassier, P; Chapet, O; Chekrine, T; De Bari, B; Kulisa, M; Mornex, F | 1 |
| Al-Barrak, J; Gilks, CB; Hoskins, P; Lau, H; Santos, JL; Swenerton, KD; Tinker, A | 1 |
| Dawson, JL; Field, TL; Fields, KK; Goldstein, SC; Kim, J; Lush, RM; Maddox, BL; Neuger, AM; Partyka, JS; Perkins, JB; Simonelli, CE; Sullivan, DM | 1 |
| Darzynkiewicz, Z; Dobrucki, J; Rybak, P; Traganos, F; Zhao, H | 1 |
| Cufer, T; Kern, I; Knez, L; Ovčariček, T; Sadikov, A; Sodja, E | 1 |
| Acker, T; Banik, N; Bogenrieder, T; Eberhardt, F; Eschbach, C; Fink, TH; Heigener, DF; Huber, RM; Hummler, S; Ittel, T; Schroeder, M; Schweisfurth, H; Steinhauer, EU; Virchow, JC; Waller, C; Wolf, M | 1 |
| Bian, ML; Higuma, C; Isaka, K; Ito, H; Liang, J; Nishi, H; Sasaki, T | 1 |
| Ceciliano, A; Chantada, GL; Dominguez, J; Fandino, AC; Millan, N; Schaiquevich, P; Taich, P; Villasante, F | 1 |
| Spigel, DR | 1 |
| Kitao, A; Matsumoto, K | 1 |
| Akamatsu, H; Endo, M; Kenmotsu, H; Murakami, H; Naito, T; Nakajima, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tsuya, A; Wakuda, K; Yamamoto, N | 1 |
| Abonyi-Tóth, Z; Katona, L; Kovács, G; Moldvay, J; Rokszin, G | 1 |
| Curtin, J; Downey, A; Edwards, S; Kwa, M; Muggia, F; Reich, E; Wallach, R | 1 |
| Aisner, J; Axelrod, RS; Dahlberg, SE; Gounder, M; Owonikoko, TK; Ramalingam, SS; Rausch, PG; Rubin, EH; Schiller, JH; Wang, XV | 1 |
| Arola, M; Clausen, N; Harila-Saari, A; Holm, S; Kivivuori, SM; Lähteenmäki, P; Lannering, B; Lönnqvist, T; Porkholm, M; Riikonen, P; Saarinen-Pihkala, UM; Schomerus, E; Sehested, A; Thomassen, H; Thorarinsdottir, HK; Valanne, L; Wojcik, D | 1 |
| Audisio, E; Boccadoro, M; Bruno, B; Crisà, E; Ferrero, D; Festuccia, M; Frairia, C; Gatti, T; Giai, V; Marmont, F; Passera, R; Riera, L | 1 |
| Ausch, C; Bajna, E; Brenner, S; Buxhofer-Ausch, V; Hamilton, G; Jäger, W; Klameth, L; Reiner, A; Riha, J; Schölm, M; Thalhammer, T | 1 |
| Chakravarty, A; Mettetal, JT; Palani, S; Patel, M; Shyu, WC; Yang, J | 1 |
| Adiguzel, R; Andreana, PR; Arslan, Z; Ates, M; Bemis, T; Bercovitch, LG; Bögli, S; Boucherez, J; Boudouf, S; Briat, JF; Brown, BM; Busemann, A; Buters, J; Byers, JS; Cairo, MS; Carrier, F; Chalmers, JJ; Chang, E; Chen, J; Chen, Y; Christenson, MK; Cielecka-Piontek, J; Cole, PA; Cooper, BS; Davis, PH; De Silva, RA; Decato, S; DeFries, RS; Demir, V; Denic, A; Deserno, M; Dickey, AM; Diss, E; Eberlein, B; Eyerich, S; Faluvegi, G; Farlow, MR; Fletcher, JW; Francetic, T; Furlan, L; Garbacki, P; Gartung, A; Garvin, JH; Gates, L; Gaymard, F; Ghetti, B; Gibson, MP; Griffin, RG; Hamed, M; Hammad, LA; Hammond, GB; Han, J; Hann, R; Hao, N; Harrison, LA; Heidecke, CD; Hutchins, GD; Inlow, M; Irmer, H; Jani, P; Jara-Cavieres, A; Jawadi, H; Jiang, Q; Jiang, Y; Kameda, T; Keeler, EG; Kim, H; Kim, R; Kim, S; Kinney, PL; Krause, A; Kumar, V; Kwok, Y; Lam, T; Lanni, F; Le May, M; Lee, A; Lee, JF; Lee, MJ; Leontyev, IV; Li, Q; Li, X; Liu, J; Liu, NK; Lominadze, D; Lösche, M; Lu, QB; Lu, Y; Lu, Z; Mach, H; Madsen, E; Marletta, M; Marlier, ME; McDonald, BC; McKay, IS; Mckenzie, CL; Mecozzi, S; Menges, P; Meyers, D; Michaelis, VK; Montooth, KL; Moore, LR; Morgan, JK; Morris, E; Movahed, M; Nalabothula, N; Narayanan, S; Nguyen, D; Nho, K; Oken, B; Ong, TC; Osborne, LS; Paczkowska, M; Park, EK; Pennino, D; Peters, S; Potluri, LP; Qin, C; Radhakrishnan, K; Randerson, JT; Rantanen, J; Reyt, G; Ring, J; Risacher, SL; Rodriguez, M; Saykin, AJ; Schmidt-Weber, CB; Sengelaub, DR; Shatters, RG; Shen, L; Shen, V; Shindell, DT; Stuchebrukhov, AA; Swaminathan, S; Takahashi, K; Talaczyńska, A; Tallman, EF; Tan, C; Terry, SF; Trabbic, KR; Trease, AJ; Tretter, C; Uitto, J; Váradi, A; von Bernstorff, W; Voulgarakis, A; Wagenhofer, M; Wahbeh, H; Wang, EN; Wang, X; Wells, RJ; West, JD; Williams, PS; Wolff, JE; Wootla, B; Xu, B; Xu, XM; Yoder, KK; Zalewski, P; Zan, GH; Zborowski, M; Zhang, HH; Zhang, W; Zhao, J; Zoecklein, L | 1 |
| Chen, S; Guan, M; Jia, N; Shao, Y; Wang, Y | 1 |
| Carrasco, R; Cruz, O; de Torres, C; Guillen, A; Lavarino, C; Mañé, S; Mora, J; Parareda, A; Rios, J; Salvador, H; Suñol, M; Vancells, M | 1 |
| Busse, PM; Ebb, DH; Friedmann, AM; Ladra, MM; Lucas, JT; MacDonald, SM; Marcus, KJ; Tarbell, NJ; Yock, TI | 1 |
| de Jong, J; Neefjes, J; Pang, B; Qiao, X; Wessels, LF | 1 |
| Bongiovanni, A; Burgio, MA; Califano, R; Carloni, F; Casanova, C; Cavallo, G; Di Battista, M; Genestreti, G; Kazushige, W; Kenmotsu, H; Korkmaz, T; Metro, G; Roopa, K; Scarpi, E; Selcuk, S; Tiseo, M | 1 |
| Bianco, V; Francini, E; Ghiribelli, C; Laera, L; Luzzi, L; Martellucci, I; Paladini, P; Petrioli, R; Roviello, G; Voltolini, L | 1 |
| Blomen, V; Brummelkamp, TR; Hoogstraat, M; Janssen, L; Lips, EH; Neefjes, J; Pang, B; Qiao, X; van der Zanden, SY; Wessels, L; Wijdeven, RH | 1 |
| Bond, MC; Felgenhauer, JL; Femino, JD; Gorlick, R; Krailo, MD; Laack, NN; Marina, N; Mascarenhas, L; Meyer, J; Ranganathan, S; Villaluna, D; Womer, RB | 1 |
| Chekerov, R; Ismaeel, F; Richter, R; Roots, I; Sehouli, J; Siepmann, T; Woopen, H | 1 |
| Goto, K; Hida, T; Imamura, F; Kiura, K; Kozuki, T; Mori, K; Nakagawa, K; Nishio, M; Ohe, Y; Okamoto, H; Satouchi, M; Sawa, T; Seto, T; Shibata, T; Takahashi, T; Takeda, K; Tamura, T; Tanaka, H; Yoshimura, N | 1 |
| Li, Q; Sun, L; Wen, F; Zhang, P; Zheng, H; Zhou, J; Zhou, K | 1 |
| Honavar, SG; Mulay, K; Rao, R; Reddy, VAP | 1 |
| Brandetti, E; Cifaldi, L; Ognibene, M; Pezzolo, A; Pistoia, V; Veneziani, I | 1 |
| Altman, JK; Broun, ER; Carroll, MP; Karp, JE; Kaufmann, SH; Ketterling, RP; Lazarus, HM; Litzow, MR; Luger, SM; Paietta, EM; Pratz, KW; Rowe, JM; Rybka, WB; Tallman, MS; Tun, HW; Wang, XV; Zhang, Y | 1 |
| Nazha, B; Owonikoko, TK | 1 |
| Castellano, G; Torrens, F | 1 |
| Dhagat, S; Eswari, JS; Yadav, M | 1 |
| Cheon, JE; Choi, JY; Choi, YH; Hong, CR; Hong, KT; Kang, HJ; Kim, IH; Kim, SK; Lee, YJ; Park, JD; Park, KD; Park, SH; Phi, JH; Shin, HY; Wang, KC | 1 |
| Kiianitsa, K; Maizels, N | 1 |
| Cramer-van der Welle, CM; Groen, HJM; Schramel, FMNH; van de Garde, EMW; van Leeuwen, AS | 1 |
| Arrieta, O; Lara-Mejía, L; Zatarain-Barrón, ZL | 1 |
| Chen, H; Horita, N; Takeshi, K | 1 |
| Baize, N; Chouaid, C; Monnet, I | 1 |
| Fang, Z; He, M; Liu, M; Liu, Q; Peng, J; Wei, Y; Wu, B; Yi, F; Zhang, W | 1 |
| Banerjee, S; Datta, S; Jahnavi, J; Maity, TR; Samanta, A | 1 |
| Bonnabry, P; Fleury-Souverain, S; Guillarme, D; Maurin, J; Rudaz, S | 1 |
| Chopra, M; Kaur, S; Rajoria, P | 1 |
| Ebinger, M; Fuchs, J; Heinz, AT; Klingebiel, T; Koscielniak, E; Kratz, CP; Ljungman, G; Münter, MW; Pajtler, KW; Rößler, J; Schönstein, A; Seitz, G; Sparber-Sauer, M; Stegmaier, S; Timmermann, B; Vokuhl, C; von Kalle, T | 1 |
| Gerner-Rasmussen, J; Hansen, O; Holm, B; Jeppesen, N; Langer, SW; Mau-Sørensen, M; McCulloch, T; Nielsen, HA; Nyhus, CH; Rytter, C; Wedervang, K | 1 |
28 review(s) available for topotecan and etoposide
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
DNA topoisomerase inhibitors.
Topics: Animals; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Interactions; Drug Resistance; Etoposide; Humans; Irinotecan; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 1994 |
Future directions in the chemotherapy of ovarian cancer.
Topics: Administration, Oral; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Europe; Female; Forecasting; Gemcitabine; Humans; Injections, Intraperitoneal; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Time Factors; Topotecan; Vinblastine; Vinorelbine | 1997 |
["State-of-the-art" chemotherapy for small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vincristine | 1997 |
Topotecan in combination chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Paclitaxel; Suramin; Topoisomerase I Inhibitors; Topotecan | 1997 |
[Pharmacokinetic monitoring].
Topics: Antineoplastic Agents; Body Mass Index; Camptothecin; Colorectal Neoplasms; Drug Interactions; Drug Monitoring; Etoposide; Fluorouracil; Humans; Irinotecan; Liver; Paclitaxel; Topotecan | 2000 |
Pharmacokinetically guided administration of chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Busulfan; Carboplatin; Cisplatin; Etoposide; Fluorouracil; Humans; Topotecan | 2000 |
Dose-intensive approaches to ovarian cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Prognosis; Survival Analysis; Topotecan | 1999 |
Paclitaxel-based three-drug combinations for the treatment of small cell lung cancer: a review of the Sarah Cannon Cancer Center experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Etoposide; Humans; Lung Neoplasms; Paclitaxel; Topotecan | 2001 |
Treatment of advanced ovarian cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Liposomes; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Topotecan | 2001 |
Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2001 |
The role of gemcitabine-based doublets in the management of ovarian carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine | 2002 |
Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan | 2002 |
Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Infant; Male; Melphalan; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Neoplasm Staging; Pilot Projects; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Rhabdomyosarcoma; Salvage Therapy; Sarcoma; Soft Tissue Neoplasms; Survival Rate; Topotecan; Treatment Outcome; Vincristine | 2001 |
Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Complementary Therapies; Cytochrome P-450 Enzyme System; Dacarbazine; Etoposide; Humans; Idarubicin; Neoplasms; Tamoxifen; Temozolomide; Thalidomide; Topotecan | 2002 |
Epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ifosfamide; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Practice Guidelines as Topic; Tamoxifen; Taxoids; Topotecan; Vinblastine; Vinorelbine | 2002 |
The role of topotecan in the treatment of advanced cervical cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Drug Synergism; Etoposide; Female; Humans; Paclitaxel; Topotecan; Uterine Cervical Neoplasms | 2003 |
In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Carcinoma, Small Cell; Cell Proliferation; Etoposide; Humans; Ifosfamide; Imatinib Mesylate; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, Nude; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Topotecan; Transplantation, Heterologous | 2005 |
Recurrent ovarian cancer: how important is it to treat to disease progression?
Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Recurrence; Risk; Taxoids; Time Factors; Topotecan | 2004 |
Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Enzyme Inhibitors; Etoposide; Female; Humans; Ifosfamide; Irinotecan; Lymphatic Metastasis; Male; Rhabdomyosarcoma; Survival Analysis; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Treatment Outcome | 2006 |
Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials, Phase III as Topic; Etoposide; Female; Humans; Infusions, Intravenous; Lomustine; Lung Neoplasms; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ontario; Practice Guidelines as Topic; Prognosis; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Topotecan | 2007 |
Management of small-cell lung cancer: incremental changes but hope for the future.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Cranial Irradiation; Dose Fractionation, Radiation; Etoposide; Humans; Lung Neoplasms; Neoplasm Staging; Practice Guidelines as Topic; Prognosis; Radiotherapy, Adjuvant; Radiotherapy, High-Energy; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Analysis; Topotecan; Treatment Outcome | 2008 |
Double high-dose chemotherapy and stem cell transplantation in adult Wilms' tumor.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cyclophosphamide; Etoposide; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Male; Melphalan; Paclitaxel; Radiography; Salvage Therapy; Topotecan; Transplantation, Autologous; Wilms Tumor; Young Adult | 2010 |
Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology.
Topics: Adult; Antineoplastic Agents; Child; Clinical Trials as Topic; Epirubicin; Etoposide; Humans; Melphalan; Molecular Targeted Therapy; Neoplasms; Topotecan | 2011 |
[Small cell neuroendocrine carcinoma of the bladder: A case report and review of the literature].
Topics: Acute Kidney Injury; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Carcinoma in Situ; Carcinoma, Neuroendocrine; Carcinoma, Transitional Cell; Combined Modality Therapy; Emergencies; Etoposide; Humans; Lymphatic Irradiation; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Neoplasms, Multiple Primary; Prognosis; Prostatic Hyperplasia; Topoisomerase I Inhibitors; Topotecan; Urinary Bladder Neoplasms | 2011 |
The influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and overall survival in ovarian cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Polypharmacy; Randomized Controlled Trials as Topic; Survival Rate; Topotecan; Withholding Treatment; Young Adult | 2016 |
Topotecan plus Platinum-Based Chemotherapy versus Etoposide plus Platinum-Based Chemotherapy for Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Coordination Complexes; Etoposide; Humans; Lung Neoplasms; Platinum; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome | 2021 |
53 trial(s) available for topotecan and etoposide
| Article | Year |
|---|---|
Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Remission Induction; Salvage Therapy; Survival Rate; Topotecan; United States | 1996 |
Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Topotecan | 1997 |
A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 1998 |
Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cohort Studies; DNA Topoisomerases, Type II; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Topotecan | 1999 |
Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Leukemia, Myeloid; Middle Aged; Recurrence; Topotecan; Treatment Outcome | 1999 |
Evaluation of topotecan and etoposide for non-Hodgkin lymphoma: correlation of topoisomerase-DNA complex formation with clinical response.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Etoposide; Female; Humans; Isoenzymes; Lymphoma, Non-Hodgkin; Male; Middle Aged; RNA, Messenger; Topotecan; Treatment Outcome | 2001 |
Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; Etoposide; Female; Humans; Hypoxanthine Phosphoribosyltransferase; Lung Neoplasms; Male; Middle Aged; Mutation; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 2001 |
Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Survival Analysis; Topotecan; Treatment Outcome | 2001 |
A phase I trial of a 5-day schedule of intravenous topotecan and etoposide in previously untreated patients with small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Rate; Topotecan; Treatment Outcome | 2001 |
A phase I study of sequential intravenous topotecan and etoposide in lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Treatment Outcome | 2001 |
Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; DNA Fragmentation; DNA Topoisomerases, Type II; Enzyme Induction; Etoposide; Female; Humans; Leukemia; Male; Middle Aged; Mitoxantrone; Topotecan | 2002 |
A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Topotecan | 2002 |
Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Disease Progression; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Survival; Thrombocytopenia; Topotecan; Treatment Outcome | 2002 |
Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin's lymphoma: a National Cancer Institute of Canada Clinical Trials Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Topotecan | 2002 |
A phase I and pharmacodynamic study of sequential topotecan and etoposide in patients with relapsed or refractory acute myelogenous and lymphoblastic leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Chemical and Drug Induced Liver Injury; DNA Topoisomerases, Type II; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Induction; Enzyme Inhibitors; Etoposide; Female; Gastrointestinal Diseases; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Proteins; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Salvage Therapy; Topoisomerase I Inhibitors; Topotecan | 2003 |
Sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer. A multicenter phase II study.
Topics: Adult; Aged; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Time Factors; Topotecan; Treatment Outcome | 2003 |
Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Illinois; Indiana; Iowa; Lung Neoplasms; Male; Middle Aged; Minnesota; Nebraska; Neoplasm Staging; North Dakota; Paclitaxel; South Dakota; Survival Analysis; Topotecan; Treatment Outcome | 2003 |
A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Topotecan | 2003 |
Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Topotecan; Treatment Outcome | 2003 |
Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Time Factors; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Treatment Outcome | 2003 |
Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cyclophosphamide; Dacarbazine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Ifosfamide; Infant; Male; Neoplasm Recurrence, Local; Neuroblastoma; Palliative Care; Temozolomide; Topotecan; Treatment Outcome | 2004 |
Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma; Chromatography, High Pressure Liquid; Disease Progression; DNA; Etoposide; Female; Humans; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Recurrence; Time Factors; Topotecan; Treatment Outcome | 2004 |
Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane. Results from a multicenter phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Drug Administration Schedule; Etoposide; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Taxoids; Topotecan | 2005 |
Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Survival Analysis; Thrombocytopenia; Topotecan; Treatment Outcome | 2005 |
Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; DNA Topoisomerases, Type II; DNA-Binding Proteins; Etoposide; Female; Humans; Middle Aged; Organophosphorus Compounds; Ovarian Neoplasms; Quality of Life; Recurrence; Topotecan | 2005 |
A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Etoposide; Humans; Middle Aged; Neoplasms; Topotecan | 2005 |
A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Topotecan; Treatment Outcome | 2005 |
A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival; Topotecan; Treatment Outcome | 2005 |
Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organophosphorus Compounds; Paclitaxel; Topotecan | 2005 |
Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Topotecan | 2005 |
Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Etoposide; Female; Humans; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan | 2006 |
Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Topotecan | 2006 |
Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Enzyme Inhibitors; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Treatment Outcome | 2006 |
A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Radiotherapy, Adjuvant; Remission Induction; Survival Rate; Topotecan; Treatment Outcome | 2006 |
Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool; Etoposide; Female; Humans; Infant; Male; Neoplasm Recurrence, Local; Neuroblastoma; Topotecan; Treatment Outcome | 2007 |
Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality Control; Quality of Life; Radiation-Sensitizing Agents; Radiotherapy Dosage; Topotecan | 2007 |
Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Humans; Infant; Infant, Newborn; Male; Neoplasm Recurrence, Local; Neuroblastoma; Topotecan; Treatment Outcome | 2007 |
Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Dose-Response Relationship, Drug; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Severity of Illness Index; Survival Rate; Topotecan; Treatment Outcome | 2007 |
Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cytarabine; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Proteins; Poly-ADP-Ribose Binding Proteins; Topotecan | 2008 |
Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Deoxycytidine; Etoposide; Female; Gemcitabine; Germany; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Proportional Hazards Models; Quality of Life; Survival Rate; Topotecan; Treatment Outcome | 2008 |
Phase II trial of combined modality therapy with concurrent topotecan plus radiotherapy followed by consolidation chemotherapy for unresectable stage III and selected stage IV non-small-lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Etoposide; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Taxoids; Topotecan | 2009 |
Venous thromboembolism in recurrent ovarian cancer-patients: A systematic evaluation of the North-Eastern German Society of Gynaecologic Oncology Ovarian Cancer Study Group (NOGGO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Germany; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Topotecan; Venous Thromboembolism | 2009 |
Phase III study comparing sequential versus alternate administration of cisplatin-etoposide and topotecan as first-line treatment in small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Patient Compliance; Small Cell Lung Carcinoma; Survival Rate; Topotecan | 2010 |
Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Small Cell Lung Carcinoma; Survival Analysis; Topotecan; Treatment Outcome | 2011 |
Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlates.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Combined Modality Therapy; DNA Topoisomerases, Type I; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Mesna; Metabolic Clearance Rate; Middle Aged; Mucositis; Multivariate Analysis; Neoplasms; Proportional Hazards Models; Topotecan; Transplantation, Autologous; Treatment Outcome | 2011 |
Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Prognosis; Small Cell Lung Carcinoma; Topotecan | 2012 |
E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 2014 |
Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Neoplasm, Residual; Prognosis; Proportional Hazards Models; Remission Induction; Risk; Survival Analysis; Topotecan; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2014 |
Topotecan combined with Ifosfamide, Etoposide, and L-asparaginase (TIEL) regimen improves outcomes in aggressive T-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Disease-Free Survival; Etoposide; Female; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphoma, T-Cell; Male; Middle Aged; Topotecan; Treatment Outcome; Young Adult | 2015 |
Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Topotecan | 2016 |
Cost-effectiveness analysis of sensitive relapsed small-cell lung cancer based on JCOG0605 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cost-Benefit Analysis; Etoposide; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Prognosis; Quality-Adjusted Life Years; Small Cell Lung Carcinoma; Survival Rate; Topotecan | 2018 |
A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Disease-Free Survival; Etoposide; Female; Flavonoids; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Piperidines; Recurrence; Remission Induction; Salvage Therapy; Sirolimus; Topotecan; Tumor Lysis Syndrome | 2019 |
Randomized phase III trial in extended stage small cell lung cancer comparing first line platinum in combination with etoposide or topotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma; Topotecan | 2023 |
127 other study(ies) available for topotecan and etoposide
| Article | Year |
|---|---|
Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoxepins; Camptothecin; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Humans; Inhibitory Concentration 50; Male; Mice; Mice, Nude; Neoplasm Transplantation; Stereoisomerism; Structure-Activity Relationship; Topoisomerase I Inhibitors; Transplantation, Heterologous; Tumor Cells, Cultured | 1998 |
Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Availability; Biological Transport; Cell Line; Dogs; Drug Resistance, Neoplasm; Etoposide; Male; Mice; Mice, Knockout; Neoplasm Proteins | 2003 |
Inhibitors of multidrug resistance (MDR) have affinity for MDR substrates.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Biological Transport; Cell Membrane; Drug Resistance, Microbial; Drug Resistance, Multiple; Ligands; Models, Molecular | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
Topics: Candida albicans; Membrane Transport Proteins; Saccharomyces cerevisiae; Structure-Activity Relationship; Substrate Specificity | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
New tricks for an old natural product: discovery of highly potent evodiamine derivatives as novel antitumor agents by systemic structure-activity relationship analysis and biological evaluations.
Topics: Antineoplastic Agents, Phytogenic; Biological Products; Cell Line, Tumor; Drug Screening Assays, Antitumor; Evodia; Humans; Quinazolines; Structure-Activity Relationship | 2012 |
Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM).
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Drug Discovery; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Glioblastoma; Humans; Models, Molecular; Molecular Conformation; Quinazolines; Structure-Activity Relationship; Temozolomide; Urea | 2015 |
Discovery and Mechanistic Study of Tailor-Made Quinoline Derivatives as Topoisomerase 1 Poison with Potent Anticancer Activity.
Topics: Antineoplastic Agents; Cell Line, Tumor; DNA Breaks, Double-Stranded; DNA Topoisomerases, Type I; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Point Mutation; Topoisomerase I Inhibitors | 2019 |
Natural Product Evodiamine with Borate Trigger Unit: Discovery of Potent Antitumor Agents against Colon Cancer.
Topics: | 2020 |
Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Humans; Irinotecan; Lung Neoplasms; Small Cell Lung Carcinoma | 2022 |
Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line.
Topics: Amsacrine; Aphidicolin; Blotting, Western; Camptothecin; Colony-Forming Units Assay; Cycloheximide; Daunorubicin; Deoxyadenosines; Dichlororibofuranosylbenzimidazole; Diterpenes; DNA Polymerase II; DNA Replication; Drug Synergism; Etoposide; Female; Humans; Leukemia, Promyelocytic, Acute; Mutagens; RNA; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured | 1991 |
SEQPWR and SEQOPR: computer programs for design of maximum information trials based on group sequential logrank tests.
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Data Interpretation, Statistical; Etoposide; Feasibility Studies; Follow-Up Studies; Humans; Linear Models; Lung Neoplasms; Programming Languages; Research Design; Sensitivity and Specificity; Software; Survival Rate; Topotecan | 1995 |
Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens.
Topics: Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Aphidicolin; Camptothecin; Carmustine; Cell Cycle; Cell Death; Cell Line; Cisplatin; Cricetinae; Cricetulus; DNA Damage; DNA Repair; DNA, Neoplasm; Doxorubicin; Drug Synergism; Etoposide; Fibroblasts; Hydroxyurea; Lung; Melphalan; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 1994 |
Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Computer Simulation; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Antagonism; Drug Synergism; Etoposide; Humans; Paclitaxel; Teratocarcinoma; Topotecan; Tumor Cells, Cultured; Vincristine | 1994 |
Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent.
Topics: Amsacrine; Antineoplastic Agents; Camptothecin; DNA Probes; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Resistance; Etoposide; Humans; Immunoblotting; Leukemia; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured | 1994 |
Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Agents; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Thrombocytopenia; Topotecan | 1996 |
Cytotoxic efficacy with combinations of topoisomerase I and topoisomerase II inhibitors in sensitive and multidrug-resistant L1210 mouse leukemia cells.
Topics: Amsacrine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Multiple; Drug Synergism; Enzyme Inhibitors; Etoposide; Leukemia L1210; Mice; Mitoxantrone; Topoisomerase I Inhibitors; Topotecan | 1996 |
The significance of the sequence of administration of topotecan and etoposide.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Survival; Cells, Cultured; Cricetinae; Drug Synergism; Enzyme Inhibitors; Etoposide; Fibroblasts; Lung; Topoisomerase I Inhibitors; Topotecan | 1996 |
Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Enzyme Induction; Etoposide; Female; Humans; Isoenzymes; Mice; Mice, Nude; Neoplasm Proteins; Topoisomerase II Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured; Up-Regulation | 1997 |
Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions.
Topics: Affinity Labels; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Biotin; Camptothecin; Caspase 3; Caspase 7; Caspases; Cisplatin; Cysteine Endopeptidases; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Fas Ligand Protein; fas Receptor; Flow Cytometry; Humans; Lamin Type B; Lamins; Leukemia-Lymphoma, Adult T-Cell; Membrane Glycoproteins; Methotrexate; Neoplasm Proteins; Nuclear Proteins; Oligopeptides; Poly(ADP-ribose) Polymerases; Staurosporine; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured | 1997 |
Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Humans; In Vitro Techniques; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1998 |
Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines.
Topics: Antineoplastic Agents; Camptothecin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Neuroblastoma; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured | 2000 |
Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Doxorubicin; Ellipticines; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Mice; Mice, Nude; Neoplasm Metastasis; Paclitaxel; Pleural Neoplasms; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2000 |
Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A.
Topics: Antineoplastic Agents; Breast; Breast Neoplasms; Carboplatin; Cell Division; Cell Line; Cell Line, Transformed; Cell Survival; Cisplatin; Cyclic AMP-Dependent Protein Kinase Type II; Cyclic AMP-Dependent Protein Kinases; Docetaxel; Doxorubicin; Epithelial Cells; Etoposide; Female; Genes, erbB-2; Humans; Oligodeoxyribonucleotides, Antisense; Paclitaxel; Receptor, ErbB-2; Taxoids; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured | 2000 |
Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.
Topics: Antineoplastic Agents; Biopsy; Camptothecin; Cell Division; Colon; Colonic Neoplasms; Culture Techniques; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Doxorubicin; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Thymidine; Topoisomerase I Inhibitors; Topotecan; Tritium; Tumor Cells, Cultured | 2000 |
Anti-neoplastic activity of topotecan versus cisplatin, etoposide and paclitaxel in four squamous cell cancer cell lines of the female genital tract using an ATP-Tumor Chemosensitivity Assay.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Etoposide; Female; Humans; Luminescent Measurements; Paclitaxel; Topotecan; Tumor Cells, Cultured; Uterine Cervical Neoplasms; Vulvar Neoplasms | 2000 |
Action of topoisomerase targeting drugs on non-Hodgkin's lymphoma and leukemia. Correlation of clinical and cell culture studies.
Topics: Acute Disease; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Cytarabine; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Isoenzymes; Leukemia; Leukocytes; Lymphoma, Non-Hodgkin; Mitoxantrone; Polymerase Chain Reaction; RNA, Messenger; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 2000 |
Clear cell carcinoma of the ovary: a remarkable case.
Topics: Adenocarcinoma, Clear Cell; Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Cisplatin; Etoposide; Female; Humans; Ovarian Neoplasms; Quality of Life; Topotecan | 2001 |
Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Phytogenic; Cystadenocarcinoma, Serous; Etoposide; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Palliative Care; Prospective Studies; Topotecan | 2001 |
Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer.
Topics: Amino Acid Substitution; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclophosphamide; DNA Mutational Analysis; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Ifosfamide; Isoenzymes; Ki-67 Antigen; Life Tables; Lung Neoplasms; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Mutation, Missense; Neoplasm Proteins; Paclitaxel; Point Mutation; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Teniposide; Topotecan; Treatment Outcome; Vault Ribonucleoprotein Particles | 2001 |
Antitumor activity of XR5944, a novel and potent topoisomerase poison.
Topics: Aminoquinolines; Animals; Antigens, Neoplasm; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Indenes; Inhibitory Concentration 50; Injections, Intraperitoneal; Injections, Intravenous; Isoenzymes; Lung Neoplasms; Mice; Mice, Nude; Phenazines; Remission Induction; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line; Checkpoint Kinase 1; DNA Repair; Doxorubicin; Doxycycline; Enzyme Inhibitors; Etoposide; Flow Cytometry; G2 Phase; Humans; Nucleic Acid Synthesis Inhibitors; Paclitaxel; Protein Kinases; Protein Serine-Threonine Kinases; S Phase; Signal Transduction; Topoisomerase I Inhibitors; Topotecan | 2002 |
Model for time dependency of cytotoxic effect of CHS 828 in vitro suggests two different mechanisms of action.
Topics: Antineoplastic Agents; Cell Division; Cyanides; Etoposide; Guanidines; Humans; Paclitaxel; Time Factors; Topotecan; Tumor Cells, Cultured | 2001 |
Cell-based assays for identification of novel double-strand break-inducing agents.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Cycle; DNA Damage; DNA Repair; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Etoposide; Idarubicin; Mutation; Saccharomyces cerevisiae; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 2002 |
X-ray repair cross-complementing gene I protein plays an important role in camptothecin resistance.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; DNA Repair; DNA-Binding Proteins; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Humans; KB Cells; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Topotecan; Transfection; X-ray Repair Cross Complementing Protein 1 | 2002 |
Chemotherapy and pregnancy.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cytarabine; Daunorubicin; Doxorubicin; Enzyme Inhibitors; Etoposide; Female; Fetus; Humans; Nucleic Acid Synthesis Inhibitors; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Topotecan; Trastuzumab; Vinblastine; Vincristine | 2002 |
Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
Topics: Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Nucleus; Cell Survival; Comet Assay; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Etoposide; Fluorescent Antibody Technique; Humans; K562 Cells; Microscopy, Confocal; Mitoxantrone; Topotecan | 2002 |
Recurrent ovarian cancer as chronic disease.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Chronic Disease; Deoxycytidine; Doxorubicin; Enzyme Inhibitors; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Recurrence; Topotecan; Trastuzumab | 2002 |
Development of a real-time in vivo transcription assay: application reveals pregnane X receptor-mediated induction of CYP3A4 by cancer chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Induction; Etoposide; Genes, Reporter; Humans; Male; Mice; Mice, Inbred C57BL; Mixed Function Oxygenases; Pregnane X Receptor; Rats; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; RNA, Messenger; Tamoxifen; Topotecan; Transcription, Genetic | 2002 |
Detection of topoisomerase inhibitor-induced DNA strand breaks and apoptosis by the alkaline comet assay.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Survival; CHO Cells; Comet Assay; Cricetinae; DNA Damage; DNA Fragmentation; Ellipticines; Enzyme Inhibitors; Etoposide; Formazans; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 2002 |
VIII International Conference on malignant lymphoma. June 12-15, 2002 Lugano, Switzerland.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Humans; Lymphoma; Lymphoma, Mantle-Cell; Middle Aged; Paclitaxel; Prednisone; Rituximab; Time Factors; Topotecan; Treatment Outcome; Vincristine | 2002 |
Unexpected pleural effusions in 3 pediatric patients treated with STI-571.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Camptothecin; Child; Combined Modality Therapy; Edema; Enzyme Inhibitors; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Irinotecan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemic Infiltration; Lung Neoplasms; Male; Neoplasm Proteins; Neuroectodermal Tumors, Primitive; Piperazines; Pleural Effusion; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction; Sarcoma, Ewing; Testis; Topotecan | 2002 |
Commentary: topoisomerases as targets in acute leukemia: I, II, I plus II or none?
Topics: Acute Disease; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; DNA Topoisomerases, Type I; DNA, Neoplasm; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Leukemia; Neoplasm Proteins; Remission Induction; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Treatment Outcome | 2003 |
Induction of long-term remission of a relapsed childhood B-acute lymphoblastic leukemia with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Burkitt Lymphoma; Child; Combined Modality Therapy; Cytarabine; Dexamethasone; Etoposide; Humans; Immunotherapy; Leukemic Infiltration; Male; Meninges; Methotrexate; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Testis; Topotecan; Transplantation, Autologous; Vindesine | 2003 |
The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells.
Topics: Animals; Antineoplastic Agents; BRCA1 Protein; Busulfan; Camptothecin; Cell Division; Cell Line; Doxorubicin; Etoposide; Fibroblasts; Gene Deletion; Genes, BRCA1; Mice; Mitoxantrone; Topotecan; Tumor Suppressor Protein p53 | 2003 |
Topotecan as first-line therapy for small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Small Cell; Cisplatin; Etoposide; Forecasting; Humans; Lung Neoplasms; Paclitaxel; Platinum; Topotecan | 2003 |
Synergistic cytotoxicity of pyrazoloacridine with doxorubicin, etoposide, and topotecan in drug-resistant tumor cells.
Topics: Acridines; Agar; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Catalysis; Cell Line, Tumor; Cell Nucleus; Clinical Trials as Topic; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Superhelical; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; Humans; Inhibitory Concentration 50; Pyrazoles; Topotecan | 2004 |
Quality of life evaluations in patients with ovarian cancer during chemotherapy treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cohort Studies; Doxorubicin; Etoposide; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Quality of Life; Topotecan | 2004 |
A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; DNA Topoisomerases, Type I; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Lymphocytes; Male; Middle Aged; Neoplasms; Paclitaxel; Topotecan | 2004 |
Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Topotecan | 2005 |
Topotecan combination chemotherapy in two new rodent models of retinoblastoma.
Topics: Animals; Animals, Newborn; Antineoplastic Agents; Apoptosis; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Etoposide; Eye; Humans; Mice; Mice, Knockout; Rats; Retinal Neoplasms; Retinoblastoma; Time Factors; Topotecan; Vincristine; Xenograft Model Antitumor Assays | 2005 |
Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1.
Topics: Adenoviridae; Antineoplastic Agents, Phytogenic; Cell Hypoxia; Cell Line, Tumor; Cell Nucleus; Drug Resistance, Neoplasm; Etoposide; Genetic Vectors; Green Fluorescent Proteins; Humans; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Isoquinolines; Neoplasms; Oxygen; Sequence Deletion; Topotecan; Transcriptional Activation | 2006 |
Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children.
Topics: Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Deoxycytidine; Dexamethasone; Drug Evaluation; Drug Synergism; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infant; Leukemia-Lymphoma, Adult T-Cell; Male; Methylprednisolone; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recombinant Proteins; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Thiotepa; Topotecan; Treatment Outcome; Vidarabine; Vinblastine | 2005 |
High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy.
Topics: Adolescent; Adult; Animals; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody Formation; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin G; Immunosuppressive Agents; Immunotherapy; Infant; Male; Melphalan; Mice; Neuroblastoma; Retrospective Studies; Thiotepa; Topotecan; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine; Whole-Body Irradiation | 2007 |
Effects of drug combinations on smooth muscle cell proliferation: an isobolographic analysis.
Topics: Algorithms; Cell Proliferation; Cell Survival; Cells, Cultured; Cladribine; Coronary Vessels; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Growth Inhibitors; Humans; Myocytes, Smooth Muscle; Sirolimus; Topotecan | 2006 |
Reponses to topoisomerase-I inhibitors in extensive small-cell lung cancer: chance or chromosomes?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Enzyme Inhibitors; Etoposide; Humans; Lung Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2006 |
[From ASCO and WCLC 2005 to clinical practice: "conventional" treatments].
Topics: Administration, Oral; Age Factors; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung; Lung Neoplasms; Mediastinoscopy; Meta-Analysis as Topic; Middle Aged; Neoplasm Staging; Palliative Care; Pneumonectomy; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Taxoids; Time Factors; Topotecan | 2006 |
Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Carboplatin; Cerebral Ventricle Neoplasms; Combined Modality Therapy; Consciousness Disorders; Cranial Irradiation; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Etoposide; Female; Gemcitabine; Germinoma; Hematopoietic Stem Cell Transplantation; Humans; Hypophysectomy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pituitary Neoplasms; Temozolomide; Thiotepa; Topotecan | 2008 |
Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Drug Interactions; Etoposide; Female; Humans; Liver; Male; Middle Aged; Models, Theoretical; Neutropenia; Neutrophils; Paclitaxel; Sex Characteristics; Taxoids; Topotecan | 2006 |
Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Epirubicin; Etoposide; Follow-Up Studies; Humans; Ifosfamide; Infection Control; Kaplan-Meier Estimate; Melphalan; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Postoperative Care; Retrospective Studies; Risk; Salvage Therapy; Sarcoma, Ewing; Topotecan; Transplantation Conditioning; Transplantation, Autologous; Treatment Failure; Vincristine | 2007 |
Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Survival Analysis; Thrombocytopenia; Time Factors; Topotecan | 2007 |
Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; Endpoint Determination; Etoposide; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Patient Compliance; Salvage Therapy; Topotecan | 2008 |
Developmental chemotherapy and management of recurrent ovarian cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drugs, Investigational; Enzyme Inhibitors; Etoposide; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Recurrence; Research Design; Taxoids; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2003 |
The relationship between the down-regulation of DNA-PKcs or Ku70 and the chemosensitization in human cervical carcinoma cell line HeLa.
Topics: Antigens, Nuclear; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Proliferation; Cisplatin; DNA-Activated Protein Kinase; DNA-Binding Proteins; Down-Regulation; Drug Resistance, Neoplasm; Etoposide; Gene Silencing; HeLa Cells; Humans; Ku Autoantigen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Topotecan | 2007 |
Spinocerebellar ataxia with axonal neuropathy: consequence of a Tdp1 recessive neomorphic mutation?
Topics: Animals; Antineoplastic Agents; Axons; Bleomycin; Brain; Camptothecin; Cells, Cultured; Comet Assay; Embryo, Mammalian; Etoposide; Fibroblasts; Genes, Recessive; Humans; Irinotecan; Mice; Mice, Knockout; Mutation; Phosphoric Diester Hydrolases; Polyneuropathies; RNA, Messenger; Spinocerebellar Ataxias; Topotecan | 2007 |
[Evaluation of second-line chemotherapies most often used in recurrent epithelial ovarian cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Topotecan; Treatment Outcome | 2007 |
Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis.
Topics: Administration, Oral; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Cost-Benefit Analysis; Cyclophosphamide; Doxorubicin; Etoposide; Female; Health Care Costs; Humans; Infusions, Intravenous; Insurance Claim Review; Irinotecan; Male; Middle Aged; Retrospective Studies; Topotecan; United States; Vincristine | 2008 |
Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Infant; Male; Neuroblastoma; Paclitaxel; Survival Rate; Topotecan; Transplantation Conditioning; Treatment Outcome; Vincristine; Young Adult | 2008 |
Trilateral retinoblastoma with pituitary-hypothalamic dysfunction.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Etoposide; Fatal Outcome; Female; Gestational Age; Humans; Hypothalamic Diseases; Infant; Infusions, Parenteral; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Pituitary Neoplasms; Retinal Neoplasms; Retinoblastoma; Retinoblastoma Protein; Tomography, X-Ray Computed; Topotecan; Vincristine | 2008 |
Long-term survival of a patient with small cell lung cancer after nine lines of chemotherapy and radiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome | 2008 |
WRN protects against topo I but not topo II inhibitors by preventing DNA break formation.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Bone Neoplasms; Bromodeoxyuridine; Cell Cycle; Cell Survival; Colony-Forming Units Assay; DNA Breaks; DNA Repair; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Enzyme Inhibitors; Etoposide; Exodeoxyribonucleases; Histones; Humans; Osteosarcoma; RecQ Helicases; RNA, Small Interfering; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured; Werner Syndrome Helicase | 2008 |
HIF-1alpha modulation by topoisomerase inhibitors in non-small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Enzyme Inhibitors; Etoposide; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Proto-Oncogene Proteins c-akt; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 2009 |
Future research directions for the treatment of AML.
Topics: Antineoplastic Agents; Azacitidine; Biomedical Research; Carbazoles; Carboplatin; Cytarabine; Daunorubicin; Decitabine; Enzyme Inhibitors; Etoposide; Flavonoids; Furans; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Piperidines; Quinolones; Staurosporine; Topotecan; Tretinoin | 2008 |
Topotecan-carboplatin-etoposide combination as 1st line treatment in patients with small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Dose-Response Relationship, Drug; Drug Tolerance; Etoposide; Female; Humans; Lung Neoplasms; Male; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome | 2009 |
[Effect of different chemotherapy regimens for concurrent chemoradiotherapy on locally advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Radiation Pneumonitis; Radiotherapy, Conformal; Retrospective Studies; Survival Rate; Topotecan | 2009 |
Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Count; Cell Enlargement; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Etoposide; Fluorouracil; Humans; Models, Biological; Myelopoiesis; Neoplasms; Neutrophils; Observation; Paclitaxel; Precision Medicine; Taxoids; Topotecan | 2010 |
Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression; Humans; Ifosfamide; Lung Neoplasms; Mice; Mice, Nude; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hodgkin Disease; Humans; Male; Mechlorethamine; Melphalan; Organoplatinum Compounds; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prednisone; Procarbazine; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Topotecan; Transplantation, Autologous; Vidarabine; Vinblastine; Vincristine | 2010 |
Topotecan and etoposide combination to test neuroblastoma in pediatric preclinical testing program.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Child; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Evaluation, Preclinical; Etoposide; Humans; Neuroblastoma; Topotecan | 2010 |
[Hematological toxicity of some combined chemotherapy schemes involving aranoza].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Glycosides; Hematologic Tests; Irinotecan; Lymphopenia; Male; Methylnitrosourea; Mice; Mice, Inbred BALB C; Neutropenia; Topotecan | 2010 |
Antiangiogenic combination therapy after local radiotherapy with topotecan radiosensitizer improved quality of life for children with inoperable brainstem gliomas.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Celecoxib; Child; Child, Preschool; Disease Progression; Etoposide; Glioma; Humans; Pilot Projects; Pyrazoles; Quality of Life; Radiation-Sensitizing Agents; Sulfonamides; Survival Analysis; Thalidomide; Topotecan; Treatment Outcome | 2011 |
Chemoresistance testing of human ovarian cancer cells and its in vitro model.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Gemcitabine; Humans; Models, Biological; Ovarian Neoplasms; Paclitaxel; Topotecan | 2010 |
Second high-dose chemotherapy intensification followed by hematopoietic stem cell transplantation applying a novel high-dose topotecan-based regimen in an adult Wilms' tumor patient: case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Kidney Neoplasms; Male; Melphalan; Nephrectomy; Topotecan; Wilms Tumor; Young Adult | 2011 |
Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma.
Topics: Abdominal Neoplasms; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Etoposide; Female; Humans; Ifosfamide; Infant; Kaplan-Meier Estimate; Lomustine; Male; Melphalan; Mesna; Neuroblastoma; Pilot Projects; Risk Factors; Thoracic Neoplasms; Topotecan; Treatment Outcome | 2011 |
Infratentorial brain metastases of pediatric non-epithelial malignant tumors: three case reports.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Dactinomycin; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant; Infratentorial Neoplasms; Irinotecan; Melphalan; Neoplasm Metastasis; Neuroblastoma; Rhabdomyosarcoma; Thiotepa; Topotecan; Vincristine | 2011 |
[Application of ATP-tumor chemosensitivity assay in recurrent epithelial ovarian cancer].
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Luminescent Measurements; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Sensitivity and Specificity; Survival Rate; Topotecan | 2010 |
Multifaceted chemotherapy for trilateral retinoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Cyclosporine; Cytarabine; Etoposide; Fatal Outcome; Female; Humans; Infant; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Pineal Gland; Retinal Neoplasms; Retinoblastoma; Tomography, X-Ray Computed; Topotecan; Vincristine | 2011 |
Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma.
Topics: Adenocarcinoma, Clear Cell; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Palliative Care; Topotecan; Treatment Outcome | 2011 |
Relationship of DNA damage signaling to DNA replication following treatment with DNA topoisomerase inhibitors camptothecin/topotecan, mitoxantrone, or etoposide.
Topics: Camptothecin; Cell Line, Tumor; DNA Damage; DNA Replication; Etoposide; Histones; Humans; Mitoxantrone; Phosphorylation; Signal Transduction; Topoisomerase Inhibitors; Topotecan | 2012 |
Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; DNA Repair; DNA-Binding Proteins; DNA, Neoplasm; Endonucleases; Epirubicin; Etoposide; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Pilot Projects; Prognosis; Retrospective Studies; Single-Blind Method; Slovenia; Topotecan; Treatment Outcome; Vincristine | 2012 |
The ubiquitin-conjugating enzyme E2-EPF is overexpressed in cervical cancer and associates with tumor growth.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Etoposide; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Nude; Paclitaxel; Promoter Regions, Genetic; Reference Values; RNA, Small Interfering; Topoisomerase I Inhibitors; Topoisomerase Inhibitors; Topotecan; Ubiquitin-Conjugating Enzymes; Uterine Cervical Neoplasms | 2012 |
Intra-arterial chemotherapy is more effective than sequential periocular and intravenous chemotherapy as salvage treatment for relapsed retinoblastoma.
Topics: Administration, Intravenous; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Injections, Intra-Arterial; Injections, Intraocular; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Ophthalmic Artery; Retinal Neoplasms; Retinoblastoma; Retrospective Studies; Salvage Therapy; Topotecan; Treatment Outcome; Vincristine; Young Adult | 2013 |
Treatment update in small-cell lung cancer: from limited to extensive disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Small Cell Lung Carcinoma; Topotecan | 2012 |
[Treatment of recurrent ovarian cancer].
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; Reoperation; Topotecan | 2012 |
Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Cohort Studies; Etoposide; Female; Humans; Induction Chemotherapy; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Small Cell Lung Carcinoma; Time Factors; Topotecan; Treatment Outcome | 2015 |
[Analysis of drug therapy of lung cancer in Hungary].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Etoposide; Gemcitabine; Glutamates; Guanine; Humans; Hungary; Inpatients; Insurance, Health; Lung Neoplasms; Paclitaxel; Pemetrexed; Prescription Drugs; Quinazolines; Retrospective Studies; Taxoids; Topotecan | 2013 |
Ovarian cancer in BRCA mutation carriers: improved outcome after intraperitoneal (IP) cisplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Carboplatin; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cystadenocarcinoma, Serous; Etoposide; Female; Floxuridine; Follow-Up Studies; Heterozygote; Humans; Injections, Intraperitoneal; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prognosis; Survival Rate; Topotecan | 2014 |
Radiation therapy and concurrent topotecan followed by maintenance triple anti-angiogenic therapy with thalidomide, etoposide, and celecoxib for pediatric diffuse intrinsic pontine glioma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Case-Control Studies; Celecoxib; Chemoradiotherapy; Chemotherapy, Adjuvant; Child; Child, Preschool; Etoposide; Female; Follow-Up Studies; Glioma; Humans; Infant; Male; Neoplasm Grading; Prognosis; Pyrazoles; Quality of Life; Remission Induction; Sulfonamides; Survival Rate; Thalidomide; Topotecan | 2014 |
Specific expression of OATPs in primary small cell lung cancer (SCLC) cells as novel biomarkers for diagnosis and therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blotting, Western; Brain Neoplasms; Chromogranins; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Lung; Lung Neoplasms; Organic Anion Transporters; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Small Cell Lung Carcinoma; Synaptophysin; Topotecan; Tumor Cells, Cultured | 2015 |
Dose schedule optimization and the pharmacokinetic driver of neutropenia.
Topics: Animals; Antineoplastic Agents; Docetaxel; Drug Administration Schedule; Etoposide; Humans; Male; Models, Biological; Models, Theoretical; Neutropenia; Rats, Sprague-Dawley; Taxoids; Topotecan | 2014 |
Topics: Adolescent; Adult; Animals; Antineoplastic Agents; Arachidonic Acids; Asbestos; Asbestosis; Attitude of Health Personnel; Carboplatin; Child; Child, Preschool; Curriculum; Databases, Factual; Education, Medical; Enzyme Inhibitors; Etoposide; Europe; Female; General Surgery; Germany; Hospitals, University; Humans; Ifosfamide; Lung Neoplasms; Male; Medical History Taking; Mesothelioma; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Neurons; Muscular Atrophy; Neoplasms; Neuroprotective Agents; Phospholipase A2 Inhibitors; Phospholipases A2, Cytosolic; Physical Examination; Quality Improvement; Spinal Cord Injuries; Topotecan; Universities; World Health Organization; Young Adult | 2014 |
Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Brain Neoplasms; Carboplatin; Child; Child, Preschool; Cisplatin; Cohort Studies; Consolidation Chemotherapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Immunotherapy; Induction Chemotherapy; Infant; Isotretinoin; Male; Neoadjuvant Therapy; Neoplasm Staging; Neuroblastoma; Neurosurgical Procedures; Pilot Projects; Prospective Studies; Radiotherapy; Thiotepa; Topotecan; Treatment Outcome; Vincristine | 2015 |
Proton therapy for pediatric and adolescent esthesioneuroblastoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Esthesioneuroblastoma, Olfactory; Etoposide; Female; Humans; Kaplan-Meier Estimate; Male; Meningeal Neoplasms; Nasal Cavity; Nose Neoplasms; Proton Therapy; Radiation Injuries; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Adjuvant; Retrospective Studies; Topotecan; Treatment Outcome; Vincristine; Young Adult | 2015 |
Chemical profiling of the genome with anti-cancer drugs defines target specificities.
Topics: Aclarubicin; Antineoplastic Agents; Cell Line, Tumor; Chromatin; Daunorubicin; DNA Damage; DNA, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Genome, Human; Histones; Humans; Molecular Targeted Therapy; Neoplasms; Organ Specificity; Protein Transport; Structure-Activity Relationship; Topoisomerase Inhibitors; Topotecan | 2015 |
Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Platinum Compounds; Retrospective Studies; Small Cell Lung Carcinoma; Survival Analysis; Topotecan; Treatment Outcome | 2015 |
Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Etoposide; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Neutropenia; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome | 2015 |
Genome-Wide Identification and Characterization of Novel Factors Conferring Resistance to Topoisomerase II Poisons in Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Capecitabine; Carcinoma; Chromosomal Proteins, Non-Histone; CRISPR-Cas Systems; Cyclophosphamide; DNA Helicases; DNA-Binding Proteins; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression Profiling; Genome-Wide Association Study; Humans; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Neoplasm Proteins; Nuclear Proteins; RNA Interference; RNA, Small Interfering; Sarcoma; SMARCB1 Protein; Taxoids; Topoisomerase II Inhibitors; Topotecan; Transcription Factors; Triple Negative Breast Neoplasms | 2015 |
Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Male; Pilot Projects; Sarcoma, Ewing; Soft Tissue Neoplasms; Topotecan; Vincristine | 2016 |
Eye salvage in diffuse anterior retinoblastoma using systemic chemotherapy with periocular and intravitreal topotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Etoposide; Gonioscopy; Humans; Infant; Infusions, Intravenous; Intravitreal Injections; Male; Microscopy, Acoustic; Retinal Neoplasms; Retinoblastoma; Retrospective Studies; Salvage Therapy; Topoisomerase I Inhibitors; Topotecan; Vincristine | 2018 |
Neuroblastoma Cell Lines Are Refractory to Genotoxic Drug-Mediated Induction of Ligands for NK Cell-Activating Receptors.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cisplatin; Cytotoxicity, Immunologic; DNA Damage; Etoposide; Humans; Immunotherapy, Adoptive; Irinotecan; Killer Cells, Natural; Neuroblastoma; Reactive Oxygen Species; Topotecan; Tumor Suppressor Protein p53 | 2018 |
The clinical conundrum of managing relapsed small cell lung cancer.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Carboplatin; Clinical Decision-Making; Disease Progression; Etoposide; Humans; Immunoconjugates; Irinotecan; Liver Neoplasms; Lung Neoplasms; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Piperazines; Pyrimidines; Salvage Therapy; Small Cell Lung Carcinoma; Temozolomide; Thiourea; Topotecan | 2019 |
Structure-Activity Relationships of Cytotoxic Lactones as Inhibitors and Mechanisms of Action.
Topics: Antineoplastic Agents, Phytogenic; Drug Design; Etoposide; Humans; Lactones; Ligands; Molecular Docking Simulation; Neoplasms; Paclitaxel; Sesquiterpenes; Structural Homology, Protein; Structure-Activity Relationship; Topotecan; Tubulin; Tubulin Modulators | 2020 |
Structure Based Drug Design and Molecular Docking Studies of Anticancer Molecules Paclitaxel, Etoposide and Topotecan using Novel Ligands.
Topics: Antineoplastic Agents, Phytogenic; Drug Design; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Lactones; Ligands; Molecular Docking Simulation; Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-myb; Sesquiterpenes; Structure-Activity Relationship; Topotecan | 2020 |
Tandem high-dose chemotherapy with topotecan-thiotepa-carboplatin and melphalan-etoposide-carboplatin regimens for pediatric high-risk brain tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Child; Child, Preschool; Etoposide; Female; Humans; Infant; Male; Melphalan; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Thiotepa; Topotecan; Transplantation, Autologous; Treatment Outcome | 2019 |
The "adductome": A limited repertoire of adducted proteins in human cells.
Topics: Cell Line; Cross-Linking Reagents; DNA; DNA Adducts; DNA Topoisomerases, Type I; DNA-Binding Proteins; Etoposide; Formaldehyde; High Mobility Group Proteins; Histones; Humans; Mass Spectrometry; Proteomics; RNA-Binding Proteins; Topotecan | 2020 |
Real-world treatment patterns and outcomes of patients with extensive disease small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Comorbidity; Cyclophosphamide; Deprescriptions; Docetaxel; Doxorubicin; Drug Tapering; Etoposide; Female; Functional Status; Humans; Lung Neoplasms; Male; Middle Aged; Netherlands; Paclitaxel; Practice Patterns, Physicians'; Progression-Free Survival; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Topotecan | 2020 |
Carboplatin plus etoposide or topotecan for small-cell lung cancer.
Topics: Carboplatin; Etoposide; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Topotecan | 2020 |
Carboplatin plus etoposide for sensitive relapsed small-cell lung cancer.
Topics: Carboplatin; Etoposide; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Small Cell Lung Carcinoma; Topotecan | 2020 |
Carboplatin plus etoposide for sensitive relapsed small-cell lung cancer - Authors' reply.
Topics: Carboplatin; Etoposide; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Topotecan | 2020 |
Towards establishment of a plant-based model to assess the novel anti-cancerous lead molecule(s): An in silico, in vivo and in vitro assessment of some potential anti-cancerous drugs on Lathyrus sativus L.
Topics: Colchicine; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Etoposide; Fluorouracil; Humans; Lathyrus; Methotrexate; Pemetrexed; Plant Proteins; RNA; Topotecan | 2022 |
Development and application of a liquid chromatography coupled to mass spectrometry method for the simultaneous determination of 23 antineoplastic drugs at trace levels.
Topics: Antineoplastic Agents; Busulfan; Carboplatin; Chromatography, Liquid; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Docetaxel; Doxorubicin; Epirubicin; Etoposide; Fluorouracil; Ganciclovir; Humans; Idarubicin; Ifosfamide; Irinotecan; Methanol; Methotrexate; Oxaliplatin; Paclitaxel; Pemetrexed; Tandem Mass Spectrometry; Topotecan; Vinblastine; Vincristine; Water | 2022 |
Ricolinostat suppresses proliferation, promotes apoptosis, and enhances the antiproliferative activity of topoisomerase inhibitors in cervical cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Etoposide; Female; Humans; Reactive Oxygen Species; Topoisomerase Inhibitors; Topotecan; Uterine Cervical Neoplasms | 2022 |
Second-line treatment of pediatric patients with relapsed rhabdomyosarcoma adapted to initial risk stratification: Data of the European Soft Tissue Sarcoma Registry (SoTiSaR).
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Chronic Disease; Cyclophosphamide; Etoposide; Humans; Polyketides; Recurrence; Retrospective Studies; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Topotecan | 2023 |